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Background
With the availability of the 2nd-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (ETR), it is possible
to obtain undetectable plasma viral load in HIV-1-infected treatment experienced patients with resistance mutations to NNRTIs.
The purpose of this study is to determine the proportion of patients with prior exposure to NNRTIs who may benefit from a
therapeutic regimen including ETR.
Patients and methods
Analysis of the genotypic resistance tests of patients having failed efavirenz (EFV) or nevirapine (NVP) antiretroviral-based
regimens, in a 5-year period (20072011). Susceptibility to ETR was assessed using four different algorithms: HIVdb Stanford
University HIV Drug Resistance Database, ANRS score, REGA score and Tibotec weighted genotypic score.
Results
Of 170 patients with a history of failure or abandonment of regimens containing EFV or NVP, 68 (40%) had mutations conferring
resistance to these NNRTIs (RAMs). Resistance tests were carried out from seven months before to 3 years after (X489207
days) the NNRTIs discontinuation. Of the HIV-1 subtypes identified (n67), most were were subtype B (53.7%) and G (34.3%)
RAMs found in the 68 samples successfuly genotyped: V90I (n2), A98G (n1), L100I (n7), K101E (n5), K103N (n38),
K103S (n2), V106A (n1), V106M (n1), V108I (n4), V179D (n4), Y181C (n18), Y188C (n1), Y188H (n1), G190A
(n11), G190E (n1), G190S (n1), H221Y (n6), P225H (n1), F227L (n3) and K238T (n2). In 27 (39.7%) patients only
one RAM was detected, 30 (44.1%) had 2, 6 had three mutations and 5 other patients had more than three RAMs to NNRTIs.
Susceptibility to ETR varied depending on the used algorithm:
Susceptible Intermediate resistance Resistant
ANRS 60 (88.2%) 3 (4.4%) 5 (7.4%)
HIVdb 49 (72.0%) 17 (25.0%) 2 (3.0%)
REGA 40 (58.8%) 27 (39.7%) 1 (1.5%)
Tibotec 44 (64.7%) 23 (33.8%) 1 (1.5%)
Conclusion
In this population with resistant virus to EFV and NVP, we found a low frequency of mutations conditioning severely impacting
on susceptibility to ETR. Based on these results, ETR could be a useful component of effective treatment regimens for the
majority of these patients with prior exposure to 1st-generation NNRTIs.
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